Trial Profile
A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Divozilimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Biocad
- 06 Sep 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.
- 16 Jul 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2019.